Business
Page 16 to 32 of 68 |   < PREVIOUS PAGE   NEXT PAGE >
The challenges of the changing drug discovery model. Fall 12 By Dr Mark Downs and Dr Tom Blackburn Fall 2012
The drug development industry is restructuring worldwide. This brings different ways of working and new challenges. As the industry moves away from internally focused research to an external model, project management and communication of science will often be more critical than outstanding science. There is a real danger the key skills will be lost across the world not least in the translation of potential drugs into early clinical trials.

Read More

Diverging paths, difficult choices. Winter 2012 By Dr Steve Arlington and Dr Nick Davies Winter 2012/13
Pharma is poised on a knife-edge. Major scientific and technological advances, together with socio-demographic changes, rising demand for medicines and trade liberalisation, will revive its fortunes in another decade. But in the meantime it faces some fundamental challenges – challenges that will entail making difficult decisions over the next few years.

Read More

Addressing the economic downturn through lab instrumental rental. Spring 13 By Dr John Comley Spring 2013
The majority of life sciences labs are facing an unprecedented decline in capex budgets and their subsequent ability to purchase new laboratory instruments. The default option underpinning lab instrument and equipment sales to life sciences has historically been the outright purchase model.

Read More

Academic ingenuity and corporate partnerships: new models in human health ventures bring value to all. Summer 13 By Professor Paul Agris Summer 2013
Many disapprove of science faculty at American universities procuring corporate ventures that support research, instead of primarily functioning as an instructor, mentor and basic researcher. This perception is most evident surrounding biomedical research at public universities. In addition, some object that corporate-funded projects involve student research. In contrast, harmony and accord with companies has been a staple at institutions with medical, engineering or technology within their venerable names.

Read More

Highlights from GlobalData’s CRO Benchmark Report. Fall 13 By Adam M. Dion Fall 2013
The biopharmaceutical industry is currently facing significant headwinds. The blockbuster era is over, development costs are skyrocketing, uncertainty exists around regulatory and reimbursement, patent cliffs, generic erosion and a sluggish global economy all have industry executives losing sleep at night.

Read More

The repositioning revolution: save me from extinction to find me pastures new. By Dr Monika Green and Dr Kate Hudson-Farmer Winter 2013
Cost containment and improving ways of treating people are key drivers for healthcare systems. Unfortunately, these do not often go hand in hand. Finding novel therapeutics with enhanced efficacy is both time consuming and costly – and offers low rates of success in relation to effort expended, in terms of time that needs to be invested.

Read More

Technology, Bane or Bonanza for the Pharmaceutical industry? Fall 07 By Dr Stephen Naylor, Adam W. Culbertson and Dr Stephen J. Valentine Fall 2007
Productivity in the pharmaceutical industry has long held well-documented concerns. While the adoption of new technologies into the drug discovery and development process has often been seen as a panacea this article argues that, without a true understanding of the complexities of introducing new technologies into the workplace and the ability to interpret the complex and massive data sets that are produced, then how can we expect it to be the bonanza to the pharmaceutical industry and the cure for all its woes?

Read More

Living in hard times. Winter 08 By Paul Branthwaite Winter 2008
Maintaining knowledge and experience internally is a challenge in today's financial climate, in SMEs and in big pharma. This article provides some tips on how companies can maintain their best staff or find reliable alternative options, especially at the critical level, when downsizing is inevitable or 'class acts' are unavailable

Read More

The Deming Approach to Quality. Fall 07 By John H. Van Drie Fall 2007
We explore the relevance to pharmaceutical research of the ideas of W. Edwards Deming, the statistician whose ideas on quality transformed the manufacturing sector of post-war Japan.

Read More

Implementing and Operating Large Complex Capital Projects in a Research Environment. Winter 06 By Dr Tim Peakman Winter 2006
UK Biobank is a major UK study that will recruit 500,000 volunteers aged between 40 and 69 to provide a resource to study the link between genetic factors, environment and lifestyle in the causes of health and disease.

Read More

Repositionings Role in Drug Discovery and Development. Winter 06 By Dr Louis A. Tartaglia and Dr Lee E. Babiss Winter 2006
The large number of drug candidate failures in recent years has been enormously costly for the pharmaceutical industry, but has also created the tremendous opportunity of repositioning these molecules into new disease areas.

Read More

Building Innovative Partnerships in Neglected Disease Research. Winter 06 By Prof Paul Herrling Winter 2006
While the recent biomedical revolution has given rise to significant advances in medical treatment, many neglected diseases that are endemic in underdeveloped parts of the world remain unaddressed.

Read More

Lean Six Sigma; its application to drug discovery. Spring 08 By Clare Hammond and Charles J O'Donnell Spring 08
In an increasingly competitive world, the race between pharmas to get high quality candidate drugs to market is on. Contributing to this success is the discovery phase of lead optimisation. The application of Lean and Six Sigma processes have, until now, been theorised to benefit the improvement in the rate at which drugs progress through to development and improve the quality of the clinical candidates1. It is the objective of this communication to demonstrate that this is indeed possible.

Read More

Outsourcing for innovation takes on new meaning. Winter 08 By Richard Boehner Winter 2008
Large pharmaceutical companies are moving quickly to outsource their drug discovery operations, predominantly to lower costs. This article argues that if outsourcing is done to capture value, ie developing and preserving intellectual property as a key competitive differentiation as well as increasing productivity, then costs will fall in line accordingly.

Read More

Prediction v Attrition. Fall 08 By Professor Malcolm Young Fall 2008
A substantial number of very valuable drugs have gone, or are about to go, off patent; too few good new premium drugs are coming through to market.

Read More

The timetable of Invention. Summer 06 By Dr William Bains Summer 2006
The most critical question to any investor in new technology should not be whether a technology will work. Technologies nearly always work in the end, providing they do not break fundamental laws of physics, and are not based on false discoveries to start with (like 'Polywater' and Cold Fusion). Enough time, investment and dedicated science will take almost any idea to realisation in the healthcare market, and if the market is willing to pay the price it will then make a profit.The critical question is: how long will it take?

Read More

Business
Page 16 to 32 of 68 |   < PREVIOUS PAGE   NEXT PAGE >